Europeiska unionen - svenska - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vacciner - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Europeiska unionen - svenska - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Europeiska unionen - svenska - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacciner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacciner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

zoetis animal health aps - moxidektin; prazikvantel - oral gel - 19,5 mg/g + 121,7 mg/g - butylhydroxitoluen hjälpämne; etanol, vattenfri hjälpämne; bensylalkohol hjälpämne; propylenglykoldikaprylokaprat hjälpämne; prazikvantel 121,7 mg aktiv substans; moxidektin 19,5 mg aktiv substans - kombinationer - häst

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

bayer ab - levonorgestrel - intrauterint inlägg - 19,5 mg - levonorgestrel 19,5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

intervet international b.v. - fenbendazol - oral pasta - 19 % - sorbitol hjälpämne; metylparahydroxibensoat hjälpämne; propylparahydroxibensoat hjälpämne; propylenglykol hjälpämne; glycerol hjälpämne; fenbendazol 187,5 mg aktiv substans - fenbendazol - häst

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - järn(iii)karboximaltos - injektions-/infusionsvätska, lösning - 50 mg fe/ml - järn(iii)karboximaltos 180 mg aktiv substans - järnoxid polymaltoskomplexer

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - järn(iii)karboximaltos - injektions-/infusionsvätska, lösning - 50 mg fe/ml - järn(iii)karboximaltos 180 mg aktiv substans - parenterala preparat

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - järn(iii)karboximaltos - injektions-/infusionsvätska, lösning - 50 mg fe/ml - järn(iii)karboximaltos 180 mg aktiv substans - parenterala preparat